Antibodies against T cells as therapeutics

Abstract

The invention relates to antibodies to T cells as therapeutics. The object underlying the invention is to provide antibodies for a clinical therapy for prolonging the immunosuppressive antibody effect while avoiding the formation of antiantibodies. This object is achieved by providing antibodies consisting of at least two different groups which are applied at different times and in which at least one antibody of group B differs from one antibody of group A in the constant regions of its heavy chains and wherein group A, which is first applied once or several times, has a T-cell eliminating effect, while the other group B (which is applied at a different time) has a T-cell eliminating and/or T-cell antigen modulating effect.

1 - 5 . cancelled  
     
     
         6 . A method for eliminating tumors comprising administering, to a tumor-bearing subject, a pharmaceutically effective amount of a first antibody, having binding specificity for T cells and which is capable of eliminating T cells in vivo, and 
 thereafter administering a pharmaceutically effective amount of a second antibody having binding specificity for T cells and which is capable of eliminating T cells in vivo, or is capable of modulating the antigen effect of T cells or is both capable of eliminating T cells in vivo and capable of modulating the antigen effect of T cells,    wherein said first antibody has a different constant region in its heavy chains than said second antibody, and thus belongs to a different animal species than said second antibody.